Citation: Sutcliffe S, Neace C, Magnuson NS, Reeves R, Alderete JF (2012) Trichomonosis, a Common Curable STI, and Prostate Carcinogenesis—A Proposed Molecular Mechanism. PLoS Pathogens 8(8): e1002801. doi:10.1371/journal.ppat.1002801
Editor: Joseph Heitman, Duke University Medical Center, United States of America
Published: August 9, 2012
Copyright: © Sutcliffe et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: SS was funded by the Barnes-Jewish Hospital Foundation. This work was funded in part by support from the Washington Research Foundation to JFA. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing interests: The authors have declared that no competing interests exist.
Why Study Trichomonosis and Prostate Cancer?
Trichomonosis, a sexually transmitted infection (STI) caused by the protist Trichomonas vaginalis, has significant public health relevance. The annual incidence is ∼8 million women in the United States and 170 million worldwide, with an equal number of infected male partners . Both men and women infected with T. vaginalis are at increased risk for human immunodeficiency virus infection . Recent evidence suggests this STI is associated with increased risk of prostate cancer, the most commonly diagnosed cancer and the second leading cause of cancer death among men in the United States . There is no immunity to T. vaginalis, and a hallmark of this STI agent is persistence. Most T. vaginalis infections in men are asymptomatic, and few are diagnosed and treated; thus, infections persist. In older, pre-antibiotic era studies, T. vaginalis was frequently found in prostate fluid specimens from asymptomatic male partners of women with trichomonosis, leading to the belief that the prostate might serve as the reservoir for trichomonosis in men . Trichomonosis may cause chronic prostatitis, and researchers have identified trichomonads in the prostatic urethra, glandular lumina, submucosa, and stroma  and, more recently, in benign hyperplastic prostatic tissue . They also observed foci of nonspecific acute and chronic inflammation, as well as intraepithelial vacuolization, near trichomonads, leading them to propose that trichomonosis might contribute to prostate carcinogenesis .
What Epidemiologic Evidence Links Trichomonosis to Prostate Cancer?
The α-actinin protein is one of the most immunogenic proteins of T. vaginalis. This protein is not found among other microorganisms and shares little amino acid sequence identity with its human homolog. Among Tritrichomonas suis, Candida albicans, and Saccharomyces cerevisiae, this protein has only 4.8%, 9.8%, and 11.1% overall identities, respectively. H. sapiens homologs of α-actinin have only 25% overall identity. Further, we performed epitope mapping using as probes representative sera of T. vaginalis–infected female and male patients that were highly reactive to both whole cell T. vaginalis and α-actinin by ELISAs –. Surprisingly, the female sera reacted with 13 epitopes scattered throughout the entire α-actinin protein, whereas male sera detected only 5 epitopes that were identical to a subset of those recognized by the female sera. These epitopes have no identity to other proteins in databanks. This indicates that the female and male antibody responses to α-actinin are polyclonal and recognize multiple epitopes. There is no detection using these female and male sera, singly or in combination, with purified human α-actinin protein. Therefore, a highly seropositive reaction to this protein in humans indicates exposure to T. vaginalis.
Recently, in a number of independent studies, trichomonosis history, as measured by serum antibodies against T. vaginalis α-actinin protein, was found to be associated with prostate cancer risk. In a large nested case-control study within the Health Professionals Follow-up Study, a positive relation between T. vaginalis serostatus and prostate cancer risk was found . This association was slightly stronger for high-grade disease. This study was followed by analyzing two additional populations, the Prostate Cancer Prevention Trial (PCPT)  and the Physicians' Health Study (PHS) . While the PCPT study did not observe an association, the PHS study detected significant positive associations for extraprostatic and fatal prostate cancer . It was noted that the PCPT null findings may have been due to the very early stage of prostate cancer examined in the trial. Finally, as further epidemiologic evidence for an association between trichomonosis and prostate cancer risk, African Americans, who have the highest incidence of trichomonosis , also have the highest risks of prostate cancer diagnosis and death . Thus, an accumulating body of evidence suggests that trichomonosis contributes to prostate carcinogenesis, a particularly more aggressive or fatal disease.
What Is a Possible Molecular Mechanism for T. vaginalis–Mediated Prostate Carcinogenesis?
Despite the observed relation between T. vaginalis seropositivity and prostate cancer risk, there is a dearth of knowledge regarding how this parasite might contribute to prostate carcinogenesis. We propose two synergistic molecular mechanisms. First, we hypothesize that T. vaginalis infection may contribute to carcinogenesis via inflammation, which is believed to be important for prostate cancer development . Second, we hypothesize and present preliminary data and published reports that T. vaginalis adherence or binding of specific trichomonad adhesin proteins to normal prostate epithelial cells (PECs) triggers a cell-signaling cascade through known proto-oncogenes, PIM1, c-MYC, and HMGA1, that may ultimately lead to prostate carcinogenesis –.
Does T. vaginalis Mediate Inflammation?
T. vaginalis infection is characterized by cytopathogenicity, and an influx of leukocytes and chronic inflammation . Parasite adherence to vaginal epithelial cells (VECs) induces expression of monocyte chemoattractant protein-1 and IL-8, pro-inflammatory cytokines involved in neutrophil recruitment . High levels of IL-8, leukotreine B4, and neutrophils have been found in vaginal secretions from patients with trichomonosis . Neutrophils may contribute to carcinogenesis by secreting a variety of oxygen- and nitrogen-based reactive molecules capable of damaging DNA and nearby cells . T. vaginalis attachment to VECs has also been shown to lead to elevated levels of IL-6 , a key inflammatory mediator associated with worse prostate cancer presentation/prognosis  and with prostate cancer incidence and mortality among healthy-weight men in a large prospective study . More recently, we have shown that parasite contact with PECs induces expression of IL-6 (unpublished data). The key point is that T. vaginalis infection promotes synthesis of pro-inflammatory cytokines that may be important in prostate carcinogenesis.
What of the PIM1-HMGA1-COX2 Cell-Signaling Cascade?
The PIM1 gene is a known proto-oncogene  whose encoded protein belongs to a small family of serine/threonine kinases that are unique because they are constitutively active. PIM1 is believed to be important for carcinogenesis because expression of this gene can lead to genomic instability and the preservation of potentially cancer-producing genomic alterations by promoting cell survival under conditions in which these alterations would not be normally tolerated . PIM1 may be important for prostate cancer, in particular because altered levels of PIM1 were observed in a study comparing malignant-to-benign prostate specimens by gene expression microarray and clinically stratified prostate cancer specimens by protein arrays , as well as in studies comparing malignant-to-benign prostate specimens and studies of prostate cancer tissue and cell lines using immuno-histochemistry with antibody to PIM1 . Of particular relevance for T. vaginalis infection, we have demonstrated that T. vaginalis contact leads to increased PIM1 expression in PECs (see below and Figure 1), providing a possible molecular mechanism by which T. vaginalis contributes to prostate carcinogenesis. Importantly, it has been demonstrated that PIM1 gene expression is induced by IL-6 via the JAK/STAT signaling pathway  and that T. vaginalis–induced IL-6 likely provides an additional molecular link between exposure of human PECs to T. vaginalis, stress, and cancer induction.
In this experiment, trichomonads were added to T25 confluent monolayers of PECs (lane labeled+) using a parasite to PEC ratio of 10∶1. PECs without added organisms are labeled with a minus sign (−). This ratio of 10∶1 was chosen because it has been shown to yield at least one parasite attached per epithelial cell in adherence assays and to optimally signal epithelial cells for up-regulation of expression of genes , . After visible attachment to PECs, non-adherent organisms were decanted and fresh PEC medium added followed by incubation at 37°C for an additional 30 min. The flask was then placed directly in ice for detachment of organisms, after which PECs were washed and removed from the flask for preparation of total proteins for immunoblotting using established protocols, polyclonal rabbit antibodies produced in our laboratories, and equal loading of protein onto gels, as detailed previously . Under conditions of exposure of PECs with or without T. vaginalis, no change in the amount of other cellular proteins was detected, as evidenced by no changes in the amounts of Akt and Bad, and this served to show equal amounts of total proteins loaded onto gels for SDS-PAGE and immunoblotting . Prebleed rabbit serum was used as the negative control and gave no reactivity.
The proto-oncogene HMGA1 encodes a chromatin “architectural transcription factor”  that, evidence indicates, acts downstream of PIM1 in an HMGA1-mediated prostate cancer induction pathway (Figure 2). Phosphorylation of c-MYC by the PIM1 kinase has been shown to induce binding of a PIM1/c-MYC complex to the E box in the promoter of c-MYC target genes, such as HMGA1, and induce their transcription . Both c-MYC and HMGA1 have also been found to be over-expressed in prostate cancers, suggesting the importance of the PIM1/c-MYC/HMGA1 signaling cascade in prostate carcinogenesis. Further evidence supporting a role for HMGA1 in prostate carcinogenesis includes the observation that high levels of HMGA1 in prostate cancer cells are related to enhanced proliferation and metastasis in vivo, studies suggesting that HMGA1 is involved in prostate cell chromosomal instability and rearrangements, and the fact that HMGA1 regulates transcription of a number of genes involved in various aspects of cell transformation and metastatic tumor progression. For example, the Prostate-Specific Membrane Antigen (PSMA) gene promoter has binding sites for HMGA1, and experiments have shown that transcription of both the human STAT3  and COX-2  genes are regulated in vivo by binding of the HMGA1 protein to their promoter regions. The oncogenic effects of HMGA1 may be further amplified because activation of the STAT3 gene promoter by HMGA1 (Figure 2, dashed line) may potentially lead to a chronic self-reinforcing “feed-back” stimulatory loop resulting in constitutively high levels of HMGA1 expression. As for PIM1, HMGA1 may also be important for T. vaginalis–mediated prostate carcinogenesis as part of the PIM1→c-MYC→HMGA1 signaling cascade because we have recently demonstrated that T. vaginalis contact up-regulates expression of HMGA1 in PECs (Figure 1). HMGA1 transcription is also known to be induced by cell stress and IL-6-mediated inflammation, possibly providing a further mechanism by which T. vaginalis may contribute to prostate carcinogenesis. As we have also shown that T. vaginalis induces IL-6 in PECs (unpublished data), we hypothesize that this stimulation is, likewise, due to the downstream binding of HMGA1 to the IL-6 promoter that has binding sites for the protein, thereby providing increased IL-6 expression, which can then reinforce the cascade and contribute to prostate cancer progression by a separate, related mechanism.
Production of IL-6 leads to transcriptional activation of the STAT3-PIM1-HMGA1 cascade. In this case induced transcriptional activation of the HMGA1 proto-oncogene contributes directly to prostate cancer progression via pathways involving COX2 and the prostate-specific membrane antigen. The inset shows a T. vaginalis organism adherent to a VEC, and the same mechanism of cytoadherence occurs for PECs.
We believe that COX-2 may be involved in T. vaginalis–mediated prostate carcinogenesis because we have recently shown that COX-2 expression is induced in primary human VECs upon interaction with either intact T. vaginalis or purified trichomonad adhesin AP65 . Further, HMGA1 up-regulates expression of COX-2 , and COX-2 over-expression in prostate cancer has been documented and associated with both cancer initiation and progression. Like HMGA1, COX-2 over-expression has also been demonstrated in many other cancers, including breast, colorectal, head and neck, esophageal and non-small-cell lung cancers, and prostatic hyperplasia. COX-2 may play a role in cancer initiation and progression by affecting cell proliferation, mitosis, cell adhesion, apoptosis and immune surveillance, and/or angiogenesis. Interestingly, polyamines also regulate levels of COX-2 in human airway epithelial cells , and T. vaginalis secrete large amounts of polyamines (putrescine) during growth . Polyamines play a role in cell cycle regulation in various types of cancers. The secreted polyamines, in concert with the induced host genes, might alter cell cycle regulation and result in a proliferative phenotype. Thus, transcriptional activation of the HMGA1 proto-oncogene promotes prostate cancer progression via pathways that involve both COX2 and PSMA.
In summary, although several epidemiologic studies have observed positive associations between T. vaginalis seropositivity and prostate cancer risk, a major knowledge gap exists in understanding how T. vaginalis activates signal transduction pathways known to be associated with prostate carcinogenesis. We present testable hypotheses and a working model (Figure 2) supported by evidence  and believe that future research should investigate these novel findings at the molecular level.
- 1. Hobbs MM, Sena AC, Swygard H, Schwebke JR. (2008) Trichomonas vaginalis and trichomoniasis. In: Sexually transmitted diseases. In: Holmes KK, Sparling PF, Stamm WE, Piot P, Wasserheit JN, Corey L, Cohen MS, Watts DH, editors. Sexually transmitted diseases. New York: McGraw-Hill Medical. 771–793.
- 2. Siegel R, Naishadham D, Jemal A (2012) Cancer statistics, 2012. CA Cancer J Clin 62: 10–29. doi: 10.3322/caac.20138
- 3. Mitteregger D, Aberle SW, Makristathis A, Walochnik J, Brozek W, et al. (2012) High detection rate of Trichomonas vaginalis in benign hyperplastic prostatic tissue. Med Microbiol Immunol 201: 113–116. doi: 10.1007/s00430-011-0205-2
- 4. Gardner WA, Culberson DE, Bennett BD (1986) Trichomonas vaginalis in the prostate gland. Arch Pathol Lab Med 110: 430–432.
- 5. Stark JR, Judson G, Alderete JF, Mundodi V, Kucknoor A, et al. (2009) Trichomonas vaginalis infection and prostate cancer incidence and mortality: a prospective study in the physician's health study. J Natl Cancer Inst 101: 1–6. doi: 10.1093/jnci/djp306
- 6. Sutcliffe S, Giovannucci E, Alderete JF, Chang TH, Gaydos , et al. (2006) Plasma antibodies against Trichomonas vaginalis and subsequent risk of prostate cancer. Cancer Epidemiol Biomarkers Prev 15: 939–945. doi: 10.1158/1055-9965.epi-05-0781
- 7. Sutcliffe S, Alderete JF, Till C, Goodman PJ, Hsing AW, et al. (2009) Trichomonosis and subsequent risk of prostate cancer in the Prostate Cancer Prevention Trial. Intl J Cancer 124: 2082–2087. doi: 10.1002/ijc.24144
- 8. De Marzo AM, Platz EA, Sutcliffe S, Xu J, Gronberg H, et al. (2007) Inflammation in prostate carcinogenesis. Nature Rev Cancer 7: 256–269. doi: 10.1038/nrc2090
- 9. Diana F, Di Bernardo J, Sgarra R, Tessari MA, Rustighi A, et al. (2005) Differential HMGA expression and post-translational modifications in prostate tumor cells. Int J Oncol 26: 515–520. doi: 10.3892/ijo.26.2.515
- 10. Shah N, Pang B, Yeoh KG, Thorn S, Chen CS, et al. (2008) Potential roles for the PIM1 kinase in human cancer—a molecular and therapeutic appraisal. Eur J Cancer 44: 2144–2151. doi: 10.1016/j.ejca.2008.06.044
- 11. Valdman A, Fang X, Pang ST, Ekman P, Egevad L (2004) PIM1 expression in prostatic intraepithelial neoplasia and human prostate cancer. Prostate 60: 367–371. doi: 10.1002/pros.20064
- 12. Wang J, Kim J, Franco OE, Hayward SW, Wills ML, et al. (2010) Pim1 kinase synergizes with c-MYC to induce advanced prostate carcinoma. Oncogene 29: 2477–2487. doi: 10.1038/onc.2010.10
- 13. Kucknoor AS, Mundodi V, Alderete JF (2007) The proteins secreted by Trichomonas vaginalis and vaginal epithelial cell response to secreted and episomally expressed AP65. Cell Microbiol 9: 2586–2597. doi: 10.1111/j.1462-5822.2007.00979.x
- 14. Ryu JS, Kang JH, Jung SY, Shin MH, Kim JM, et al. (2004) Production of interleukin-8 by human neutrophils stimulated with Trichomonas vaginalis. Infect Immun 72: 1326–1332. doi: 10.1128/iai.72.3.1326-1332.2004
- 15. Dhanasekaran SM, Barrette TR, Ghosh D, Shah R, Varambally S, et al. (2001) Delineation of prognostic biomarkers in prostate cancer. Nature 412: 822–826. doi: 10.1038/35090585
- 16. Han IH, Park SJ, Ahn MH, Ryu JS (2012) Involvement of mast cells in inflammation induced by Trichomonas vaginalis via crosstalk with vaginal epithelial cells. Parasite Immunol 34: 8–14. doi: 10.1111/j.1365-3024.2011.01338.x
- 17. Azevedo A, Cunha V, Teixeira AL, Medeiros R (2011) IL-6/IL6R as a potential key signaling pathway in prostate cancer development. World J Clin Oncol 2: 384–396. doi: 10.5306/wjco.v2.i12.384
- 18. Stark JR, Li H, Kraft P, Giovannucci EL, Stampfer M, et al. (2009a) Circulating prediagnostic interleukin-6 and C-reactive protein and prostate cancer incidence and mortality. Int J Cancer 124: 2683–2689. doi: 10.1002/ijc.24241
- 19. Magnuson NS, Wang Z, Ding G, Reeves R (2010) Why target PIM1 for cancer diagnosis and treatment? Future Oncol 6: 1461–1478. doi: 10.2217/fon.10.106
- 20. Roh M, Franco OE, Hayward SW, van der Meer R, Abdulkadir SA (2008) A role for polyploidy in the tumorigenicity of PIM1-expressing human prostate and mammary epithelial cells. PLoS ONE 3: e2572 doi:10.1371/journal.pone.0002572. doi: 10.1371/journal.pone.0002572
- 21. Sansone P, Bromberg J (2012) Targeting the interleukin-6/jak/stat pathway in human malignancies. J Clin Oncol 30: 1005–1014. doi: 10.1200/jco.2010.31.8907
- 22. Reeves R, Beckerbauer L (2001) HMGI/Y proteins: flexible regulators of transcription and chromatin structure. Biochim Biophys Acta 1519: 13–29. doi: 10.1016/s0167-4781(01)00215-9
- 23. Zhang Y, Wang Z, Li X, Magnuson NS (2008) Pim-1 kinase-dependent inhibition of c-MYC degradation. Oncogene 27: 4809–4819. doi: 10.1038/onc.2008.123
- 24. Hillion J, Dhara S, Sumter TF, Mukherjee M, Di Cello F, et al. (2008) The high-mobility group A1a/signal transducer and activator of transcription-3 axis: an Achilles heel for hematopoietic malignancies? Cancer Res 68: 10121–10127. doi: 10.1158/0008-5472.can-08-2121
- 25. Tesfaye A, Di Cello F, Hillion J, Ronnett BM, Elbahloul O, et al. (2007) The high-mobility group A1 gene up-regulates cyclooxygenase 2 expression in uterine tumorigenesis. Cancer Res 67: 3998–4004. doi: 10.1158/0008-5472.can-05-1684
- 26. Cowan MJ, Coll T, Shelhamer JH (2006) Polyamine-mediated reduction in human airway epithelial migration in response to wounding is PGE2 dependent through decreases in COX-2 and cPLA2 protein levels. J Appl Physiol 101: 1127–1135. doi: 10.1152/japplphysiol.01287.2005
- 27. Garcia A, Benchimol M, Alderete JF (2005) Trichomonas vaginalis polyamine metabolism is linked to host cell adherence and cytotoxicity. Infect Immun 73: 2602–2610. doi: 10.1128/iai.73.5.2602-2610.2005
- 28. Hu XF, Li J, Vandervalk S, Wang Z, Magnuson NS, et al. (2009) PIM-1-specific mAb suppresses human and mouse tumor growth by decreasing PIM1 levels, reducing Akt phosphorylation, and activating apoptosis. J Clin Invest 119: 362–375. doi: 10.1172/jci33216